Skip to content

Tricuspid Valve Reconstruction Using the Right Atrial Appendage

Tricuspid Valve Reconstruction Using the Right Atrial Appendage

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07761273
Enrollment
30
Registered
2026-08-12
Start date
2026-04-28
Completion date
2027-04-01
Last updated
2026-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tricuspid Valve Disease

Keywords

right atrial appendage -reconstruction-tricuspid valve

Brief summary

we use part of the cardiac chambre for replacement of destroyed valve on right side of the heart

Detailed description

Tricuspid Valve Reconstruction Using the Right Atrial Appendage by harvesting appropriate size then reconstruction as bileaflet valve after reinforcement of the annulus by pericardial band then the neovalve fixed to papillary muscles of the right ventricle by artificial chorda anchored by teflon pledgets

Interventions

PROCEDURETricuspid Valve Reconstruction

Tricuspid Valve Reconstruction using right atrial appendage

tricuspid valve replacement using tissue valve

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* all patient need tricuspid valve replacement

Exclusion criteria

* patient refusal

Design outcomes

Primary

MeasureTime frameDescription
Mortality30 day post operativeperioperative and short-term mortality, with no major procedure-related surgical complication
Morbidity30 day post operative
measuring pressure gradient6 months postoperativeFollow-up echocardiography by measuring pressure gradient across the neo valve
Thromboembolic Risk checklist6 months postoperative

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026